Córdoba Raúl, Del Olmo Rodríguez Marta, Ramos Sergio, López García Alberto, Morillo Daniel, Pérez-Sáenz Maria-Angeles, Miranda Carolina, Martos Rafael, Beltrán Laura, Castillo Eva, Herrero Antonio, Gómez-Meana Alvaro, Pfang Bernadette, Short Apellaniz Jorge, Arcos-Campillo Javier
Haematology Department Hospital Universitario Fundacion Jimenez Diaz Madrid Spain.
Hospital Management Quirónsalud 4-H Network Madrid Spain.
EJHaem. 2025 Sep 3;6(5):e70129. doi: 10.1002/jha2.70129. eCollection 2025 Oct.
BACKGROUND: Healthcare is shifting from a disease-centered to patient-centered approach, and aspects of health such as quality of life (QoL) are becoming increasingly relevant. "E-Res Salud" for hematological malignancies is a value-based healthcare program aiming to improve patient experience and outcomes. The program collects e-PROMs via automatically deployed, validated questionnaires over a mobile application. METHODS: A multicenter prospective observational cohort study including 243 patients with Hodgkin and non-Hodgkin lymphoma receiving outpatient intravenous immunochemotherapy at four teaching hospitals in Madrid, Spain, of whom 121 participated in the "E-Res Salud" program. RESULTS: We found that adverse event reporting differs significantly between patients and healthcare professionals. Participants showed significantly lower rates of emergency department visits (37.2% vs. 56.6%; < 0.01) and unplanned hospital admissions (21.5% vs. 32.8%; < 0.05), as well as significantly higher rates of treatment completion and overall survival (88.4% vs. 79.5% after 18 months of follow-up; stratified hazard ratio, 2.30; 95% CI 1.25-4.22; = 0.007). CONCLUSIONS: An e-PROMS program for patients with lymphoma is associated with lower use of healthcare and improved clinical outcomes. Patients and hematologists report adverse events differently, demonstrating the importance of patient-reported outcome measurement to improve symptom management in clinical practice. : The authors have confirmed clinical trial registration is not needed for this submission.
Cochrane Database Syst Rev. 2025-6-5
Cochrane Database Syst Rev. 2024-5-30
Cochrane Database Syst Rev. 2017-10-4
Cochrane Database Syst Rev. 2017-5-23
Cochrane Database Syst Rev. 2014
Cochrane Database Syst Rev. 2025-4-22
Cochrane Database Syst Rev. 2017-10-3
Curr Oncol. 2025-5-1
JAMA Netw Open. 2024-6-3
Front Oncol. 2024-3-13
Eur J Cancer. 2023-3